Brincker H, Birkeland S A
Cancer. 1981 Jan 15;47(2):266-71. doi: 10.1002/1097-0142(19810115)47:2<266::aid-cncr2820470210>3.0.co;2-4.
In a longitudinal study, several immunologic in vitro tests were performed on peripheral lymphocytes in four patients with immunoblastic lymphadenopathy during sequential therapy with Levamisole and polychemotherapy. The percentage of T cells tended to fall with increasing disease activity, while the percentage of B cells remained almost constant. Blast transformation tests showed that both the T-cell and B-cell responses are defective and that improvement in disease status is correlated closely with an improvement of the blast transformation response. Levamisole treatment improved the blast transformation response but did not produce clinical remission in contrast to polychemotherapy, which produced clinical remission as well as improvement of the blast transformation response. No conclusions about the pathogenesis of this disease could be made in the present study. No proof was found of a primary defective T-cell function (including T-suppressor activity) although the available methods did not preclude this possibility completely.
在一项纵向研究中，对4例免疫母细胞性淋巴结病患者在左旋咪唑和联合化疗的序贯治疗期间，对外周淋巴细胞进行了多项体外免疫检测。随着疾病活动度增加，T细胞百分比趋于下降，而B细胞百分比几乎保持不变。淋巴细胞转化试验表明，T细胞和B细胞反应均有缺陷，且疾病状态的改善与淋巴细胞转化反应的改善密切相关。与联合化疗不同，左旋咪唑治疗改善了淋巴细胞转化反应，但未产生临床缓解，联合化疗则产生了临床缓解以及淋巴细胞转化反应的改善。本研究无法就该疾病的发病机制得出结论。尽管现有方法不能完全排除这种可能性，但未发现原发性T细胞功能缺陷（包括T抑制活性）的证据。
